| Dr Michael David Ball, DO | |
|
504 Nw 10th Ave., Ava, MO 65608-1359 | |
| (417) 683-4831 | |
| Not Available |
| Full Name | Dr Michael David Ball |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 44 Years |
| Location | 504 Nw 10th Ave., Ava, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700980174 | NPI | - | NPPES |
| 1700980174 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | R6B35 (Missouri) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Douglas County Public Health Services Group, Inc. | 3072423052 | 16 |
News Archive
In this interview, News-Medical talks to Dr. Brendan Horton about his latest research which has shed new light on cancer and T cells.
BioCancell, a developer of anti-cancer drugs, announced success in attaining the goals of its Phase I/IIa clinical trial of BC-819 as a treatment for pancreatic cancer, which demonstrated an excellent safety profile and preliminary efficacy.
Individual variations in genetic makeup and gut bacteria may explain the different effects of antibiotics on blood pressure, a new rat study suggests. The findings are published ahead of print in Physiological Genomics.
Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced four studies of bavituximab and its other PS-targeting antibodies have been accepted for presentation at the 101st Annual Meeting of the American Association for Cancer Research to be held April 17-21, 2010 in Washington, D.C.
› Verified 4 days ago
| Entity Name | Douglas County Public Health Services Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912904004 PECOS PAC ID: 3072423052 Enrollment ID: O20050301000128 |
News Archive
In this interview, News-Medical talks to Dr. Brendan Horton about his latest research which has shed new light on cancer and T cells.
BioCancell, a developer of anti-cancer drugs, announced success in attaining the goals of its Phase I/IIa clinical trial of BC-819 as a treatment for pancreatic cancer, which demonstrated an excellent safety profile and preliminary efficacy.
Individual variations in genetic makeup and gut bacteria may explain the different effects of antibiotics on blood pressure, a new rat study suggests. The findings are published ahead of print in Physiological Genomics.
Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced four studies of bavituximab and its other PS-targeting antibodies have been accepted for presentation at the 101st Annual Meeting of the American Association for Cancer Research to be held April 17-21, 2010 in Washington, D.C.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael David Ball, DO Po Box 1359, Ava, MO 65608-1359 Ph: (417) 683-4831 | Dr Michael David Ball, DO 504 Nw 10th Ave., Ava, MO 65608-1359 Ph: (417) 683-4831 |
News Archive
In this interview, News-Medical talks to Dr. Brendan Horton about his latest research which has shed new light on cancer and T cells.
BioCancell, a developer of anti-cancer drugs, announced success in attaining the goals of its Phase I/IIa clinical trial of BC-819 as a treatment for pancreatic cancer, which demonstrated an excellent safety profile and preliminary efficacy.
Individual variations in genetic makeup and gut bacteria may explain the different effects of antibiotics on blood pressure, a new rat study suggests. The findings are published ahead of print in Physiological Genomics.
Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced four studies of bavituximab and its other PS-targeting antibodies have been accepted for presentation at the 101st Annual Meeting of the American Association for Cancer Research to be held April 17-21, 2010 in Washington, D.C.
› Verified 4 days ago
Holli K Ruby, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 504 Nw 10th Ave., Ava, MO 65608 Phone: 417-683-4831 Fax: 417-683-1602 | |
Christine Gentry, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 806 Sw Collins Ave, Ava, MO 65608 Phone: 417-269-2293 Fax: 417-269-2296 | |
Dr. Augusta Ellice Hays, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 504 W. Broadway Ave., Ava, MO 65608 Phone: 417-683-5739 |